Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By continuing, you are declaring that you are requesting any such information.
Multiple sclerosis (MS) patients commonly experience a gradual loss of dexterity and function in their hands and arms, especially those with primary progressive multiple sclerosis (PPMS). Usually these patients also have walking limitations, so it’s crucial that they are able to use their hands and arms to complete daily activities.
A previous study on Ocrevus (ocrelizumab) resulted in lower rates of disease progression in terms of the ability to walk, brain lesion volume, and total brain volume loss in MS patients. Now researchers have done an exploratory study specifically focussed on the effects of Ocrevus (ocrelizumab) on hands and arms in PPMS.
The researchers wrote that “findings from this analysis showed that ocrelizumab (Ocrevus) mitigated progression of UE impairment in patients with PPMS”. These results are very promising for patients confined to a wheelchair, as this has a big impact on their independence and quality of life. Read more at Multiple Sclerosis News Today.